UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000060362 |
|---|---|
| Receipt number | R000069056 |
| Scientific Title | Monitoring test of salt offset jelly |
| Date of disclosure of the study information | 2026/01/15 |
| Last modified on | 2026/01/15 13:45:35 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Monitoring test of salt offset jelly
Acronym
Monitoring test of salt offset jelly
Scientific Title
Monitoring test of salt offset jelly
Scientific Title:Acronym
Monitoring test of salt offset jelly
Region
| Japan |
Condition
Condition
Healthy Adults
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Evaluate the salt (sodium) absorption inhibitory effect (salt excretion effect) on adults aged 20 years or older by intake alginate-containing jelly for 2 weeks.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Urinary sodium at the beginning of or after the intake for 2 weeks.
Key secondary outcomes
Urinary potassium, urinary Na/K ratio, BMI, Health Questionnaire (about health awareness, diet), at the beginning of or after the intake for 2 weeks.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Intake of alginate-containing jelly (containing 0.75 g of alginate) twice a day for 2 weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate.
2.Persons who are 20 years or older.
Key exclusion criteria
1.Persons who have chronic illness, receiving medication, have a serious disease history.
2.Persons who are allergic to the test food.
3.Persons who usually take a large amount of test food.
4.Persons who usually take medicine and specified health food that may have effect to salt absorption or excretion.
5.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam.
6.Persons who were judged as inappropriate for study participants by the principal investigator.
7.Persons who are pregnant, planning or hoping to be pregnant during the study period, breastfeeding.
Target sample size
150
Research contact person
Name of lead principal investigator
| 1st name | Hidenori |
| Middle name | |
| Last name | Takeshita |
Organization
Toy Medical Co., Ltd.
Division name
Representative Director
Zip code
861-4163
Address
48-1, Shijimizu, Tomiaimachi, Minami-ku, Kumamoto-City, Kumamoto, JAPAN
TEL
096-342-6477
takeshita@toymedical.jp
Public contact
Name of contact person
| 1st name | Konatsu |
| Middle name | |
| Last name | Matsushita |
Organization
Toy Medical Co., Ltd.
Division name
Marketing Department
Zip code
861-4163
Address
48-1, Shijimizu, Tomiaimachi, Minami-ku, Kumamoto-City, Kumamoto, JAPAN
TEL
096-342-6477
Homepage URL
matsushita@toymedical.jp
Sponsor or person
Institute
Toy Medical Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
INCUBATION PROGRAM 2025 (Kanagawa Prefecture)
Organization
Division
Category of Funding Organization
Local Government
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The Ethics Committee of Healthcare Systems Co., Ltd.
Address
1-14-18 Shirakane, Showa-ku, Nagoya city, Aichi, JAPAN
Tel
0368092722
soumu@hc-sys.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 01 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 01 | Month | 14 | Day |
Date of IRB
| 2026 | Year | 01 | Month | 14 | Day |
Anticipated trial start date
| 2026 | Year | 01 | Month | 16 | Day |
Last follow-up date
| 2026 | Year | 02 | Month | 28 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 01 | Month | 15 | Day |
Last modified on
| 2026 | Year | 01 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069056
